DESTINY-GASTRIC-04

NCT04704934 📎

Regimen

Experimental
trastuzumab deruxtecan (T-DXd)
Control
ramucirumab + paclitaxel

Population

HER2-positive gastric/GEJ cancer progressing on trastuzumab-based first-line therapy (re-biopsy-confirmed HER2+)

Key finding

mOS 14.7 vs 11.4 mo (HR 0.70, 95% CI 0.55-0.90, p=0.004); mPFS HR 0.74; confirmed ORR 44.3% vs 29.1%

Source: PMID 40454632

Timeline

    Guideline citations

    • NCCN GASTRIC (p.7)
    • CSCO GASTRIC 2025 (p.89)⚠️ OCR source